Journal
EXPERT OPINION ON THERAPEUTIC TARGETS
Volume 12, Issue 6, Pages 739-748Publisher
TAYLOR & FRANCIS LTD
DOI: 10.1517/14728222.12.6.739
Keywords
antitumor activity; clioquinol; copper; disulfiram; dithiocarbamate; proteasome inhibitors
Categories
Funding
- NCI NIH HHS [1R01CA120009, R01 CA120009, R03 CA112625] Funding Source: Medline
Ask authors/readers for more resources
Background: The conventional approach toward anticancer drug development is a time-consuming and expensive procedure. Objective/methods: One approach to expedite this process and achieve more affordable means is to discover new applications of existing drugs, since their pharmacokinetics and pharmacological profiles are well known. Results: Our encouraging findings in recent studies reveal anticancer activities of several copper-binding ligands including disulfiram (an antialcoholism drug), clioquinol (used to treat Alzheimer's and Huntington's diseases) and diethyldithiocarbamate (an agent for HIV-1 infection treatment). Conclusion: These in vitro and in vivo studies have demonstrated that these archaic drugs can target and react with tumor cellular copper, forming complexes that act as potent proteasome inhibitors and apoptosis inducers.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available